BioLife Solutions, Inc.
BioLife Solutions develops and markets bioproduction tools and services for cell and gene therapy industry globally. Products include biopreservation media, human platelet lysates, CellSeal vials, ThawSTAR devices, cryogenic freezers, ultra-low temperature freezers, shipping containers, and storage accessories. The company provides direct sales and distribution through third-party partners.
Overview
Sector
Medical Instruments & Supplies
Strengths
- Price to book ratio (2.89) is lower than the sector mean (3.86).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (2.31%) is significantly lower than the sector mean (8.23%).
- EV/EBITDA (165.64) is significantly higher than the sector mean (47.53).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (205.55) is significantly higher than the sector mean.
- EBITDA Margin (6.82%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 165.6 |
| Price/Free Cash Flow' | 205.6 |
| ROIC | 2.3% |
| Net Debt/EBITDA | 100.0 |